Andre Hoekema - Galapagos Sr. VP of Corporate Devel.

GLPG Stock  USD 27.64  0.48  1.71%   

SVP

Dr. Andre Hoekema is Member of the Executive Committee, Chief Business Officer at Galapagos NV. He joined Galapagos in March 2005 from Invitrogen Corporationrationration, where he was Managing Director of Corporationrationrate Development Europe. Dr. Hoekema currently also serves as a Member of the Supervisory Board of Mimetas B.V. He has 20 years of biotech experience from positions at Molecular Probes Europe, Crucell, DSM Life Sciences and MOGEN and Genentech, Inc
Age 67
Professional MarksPh.D
Address Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800
Phone32 1 534 29 00
Webhttps://www.glpg.com
Hoekema has a Doctorate in Philosophy degree from Leiden University and is the inventor of over 20 series of patent applications, resulting in 15 patents issued in the United States.

Galapagos Management Efficiency

The company has return on total asset (ROA) of (0.0238) % which means that it has lost $0.0238 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0221) %, meaning that it created substantial loss on money invested by shareholders. Galapagos' management efficiency ratios could be used to measure how well Galapagos manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Galapagos' Return On Equity is most likely to increase slightly in the upcoming years. At this time, Galapagos' Total Current Assets are most likely to increase significantly in the upcoming years. The Galapagos' current Intangible Assets is estimated to increase to about 125.1 M, while Intangibles To Total Assets are projected to decrease to 0.04.
Galapagos NV ADR currently holds 9.6 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Galapagos NV ADR has a current ratio of 8.07, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Galapagos' use of debt, we should always consider it together with its cash and equity.
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium. Galapagos operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1344 people. Galapagos NV ADR (GLPG) is traded on NASDAQ Exchange in USA. It is located in Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800 and employs 1,123 people. Galapagos is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Galapagos NV ADR Leadership Team

Elected by the shareholders, the Galapagos' board of directors comprises two types of representatives: Galapagos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galapagos. The board's role is to monitor Galapagos' management team and ensure that shareholders' interests are well served. Galapagos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galapagos' outside directors are responsible for providing unbiased perspectives on the board's policies.
Andre Hoekema, Sr. VP of Corporate Devel.
John Montana, Managing Argenta
Walid AbiSaab, Member of the Executive Committee, Chief Medical Officer
Marieke Vermeersch, Head Communication
Patrik Ringblom, Head Lead
Ellen Aar, Head Development
Dirk Naeyer, Head Operations
Annelies Missotten, Executive Officer
Alice Dietrich, Head Affairs
Philippe Alen, Senior Development
Thad CMA, CFO VP
Elizabeth Goodwin, VP Corporate Communications & Investor Relations
Michele MBA, Head Commercial
Chantal Tasset, Head Devel
Thad Huston, CFO COO
Sofie Gijsel, Head Relations
MBA MBA, COO Pres
Valeria Cnossen, Executive Counsel
Jeevan Shetty, Head Oncology
PharmD Raboisson, Head VP

Galapagos Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Galapagos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Galapagos NV ADR is a strong investment it is important to analyze Galapagos' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galapagos' future performance. For an informed investment choice regarding Galapagos Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galapagos NV ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galapagos. If investors know Galapagos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galapagos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.748
Earnings Share
(0.97)
Revenue Per Share
0.1977
Quarterly Revenue Growth
(0.50)
Return On Assets
(0.02)
The market value of Galapagos NV ADR is measured differently than its book value, which is the value of Galapagos that is recorded on the company's balance sheet. Investors also form their own opinion of Galapagos' value that differs from its market value or its book value, called intrinsic value, which is Galapagos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galapagos' market value can be influenced by many factors that don't directly affect Galapagos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galapagos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galapagos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galapagos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.